OBJECTIVES: Development and validation of an epistaxis-specific quality-of-life questionnaire (EQQoL) to evaluate the impact on quality of life of epistaxis, during hereditary hemorrhagic telangiectasia (HHT). STUDY DESIGN: Prospective clinical study using QoL instruments administered twice in HHT patients. PATIENTS AND METHODS: In total, 109 patients who had epistaxis and a clinical diagnosis of HHT according to Curacao criteria were included. Invoice of the questionnaire in 2004 and 2006 included SF-36, Jenkins` sleep scale and the new epistaxis-specific13-item EQQoL. RESULTS: EQQoL uptake rate was 98%, mean score 58/100 +- 27, and Cronbach alpha 0.96. EQQoL was sensitive to change with a strong correlation with the course of epistaxis. Factorial analysis showed that EQQoL was clearly distinct from SF-36 and Jenkins sleep scales. In stepwise multivariate ordinal logistic regression, frequency and duration of epistaxis were both associated with lower EQQoL. Conversely, visceral involvement and comorbidity had independent impact on SF-36 scores, but not on EQQoL. CONCLUSIONS: This new epistaxis-specific EQQoL questionnaire provides complementary information on the impact of HHT on patients quality of life relative to the SF-36 generic questionnaire. After international validation, the EQQoL might prove a useful tool for treatment evaluation.
OBJECTIVES: Development and validation of an epistaxis-specific quality-of-life questionnaire (EQQoL) to evaluate the impact on quality of life of epistaxis, during hereditary hemorrhagic telangiectasia (HHT). STUDY DESIGN: Prospective clinical study using QoL instruments administered twice in HHTpatients. PATIENTS AND METHODS: In total, 109 patients who had epistaxis and a clinical diagnosis of HHT according to Curacao criteria were included. Invoice of the questionnaire in 2004 and 2006 included SF-36, Jenkins` sleep scale and the new epistaxis-specific13-item EQQoL. RESULTS:EQQoL uptake rate was 98%, mean score 58/100 +- 27, and Cronbach alpha 0.96. EQQoL was sensitive to change with a strong correlation with the course of epistaxis. Factorial analysis showed that EQQoL was clearly distinct from SF-36 and Jenkins sleep scales. In stepwise multivariate ordinal logistic regression, frequency and duration of epistaxis were both associated with lower EQQoL. Conversely, visceral involvement and comorbidity had independent impact on SF-36 scores, but not on EQQoL. CONCLUSIONS: This new epistaxis-specific EQQoL questionnaire provides complementary information on the impact of HHT on patients quality of life relative to the SF-36 generic questionnaire. After international validation, the EQQoL might prove a useful tool for treatment evaluation.
Authors: Arash Abiri; Khodayar Goshtasbi; Marlon Maducdoc; Ronald Sahyouni; Marilene B Wang; Edward C Kuan Journal: Lasers Surg Med Date: 2019-08-22 Impact factor: 4.025
Authors: Basel Chamali; Helen Finnamore; Richard Manning; Michael A Laffan; Mary Hickson; Kevin Whelan; Claire L Shovlin Journal: Intractable Rare Dis Res Date: 2016-05
Authors: Roberto Zarrabeitia; Concepción Fariñas-Álvarez; Miguel Santibáñez; Blanca Señaris; Ana Fontalba; Luisa María Botella; José Antonio Parra Journal: Health Qual Life Outcomes Date: 2017-01-23 Impact factor: 3.186
Authors: Joan D Beckman; Quefeng Li; Samuel T Hester; Ofri Leitner; Karen L Smith; Raj S Kasthuri Journal: Orphanet J Rare Dis Date: 2020-07-13 Impact factor: 4.123
Authors: Rhett S Thomson; Nicole L Molin; Kevin J Whitehead; Shaelene Ashby; Leland Johnson; P Daniel Ward; Bryan R McRae; Kevin F Wilson; Jamie McDonald Journal: Laryngoscope Investig Otolaryngol Date: 2018-04-19